DTI for Injection

DTI for Injection Warnings

dacarbazine

Manufacturer:

Korea United Pharm [KR]

Distributor:

Masu
Full Prescribing Info
Warnings
It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.
Hemopoietic depression is the most common toxicity with dacarbazine.
Hepatic necrosis has been reported.
Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in